medigraphic.com
ISSN 0188-9796 (Print)

2010, Number 3

<< Back Next >>

Rev Endocrinol Nutr 2010; 18 (3)

Effect of rosiglitazone on 131I uptake in patients with differentiated thyroid carcinoma with high thyroglobulin levels and negative radioiodine scans

Segovia-Palomo A, Alamilla-Lugo L, Sosa-Caballero A, Muñoz-Solís A, García-Nicasio E, Moreno-Peña DO, Molina-Guerra JA

Language: Spanish
References: 20
Page: 146-149
PDF size: 268.92 Kb.


ABSTRACT

Background: 20-30% of patients with differentiated thyroid carcinoma lose the ability to concentrate radioactive iodine as they undergo undiferentiation. Rosiglitazone is a PPARγ agonist which in some cases succeeds in regaining the capacity to concentrate of isotope. Objective: To evaluate the effect of rosiglitazone in achieving radioidine concentration in patients with DTC with previously elevated Tg levels and negative whole body scans (WBS). Material and methods: Sixteen patients with DTC and elevated Tg levels and negative WBS were studied. They were given daily 8 mg doses of rosiglitazone for 12 weeks and then underwent radioiodine WBS along with Tg, TgAb and TSH measurements. Those who did not regain the ability to concentrate radioiodine received rosiglitazone at the same dose for 12 more weeks. Results: At the endo of the first 12 weeks 4 patients (25%) had a positive WBS, whereas in 12 (75%) it remained negative. These latter subjects went on to receive 12 more weeks of rosiglitazone and 9 completed a total of 24 weeks of treatment (3 dropped out). Of these 9 subjects, 3 regained the ability to concentrate radioiodine and 6 persisted with negative WBS. Conclusion: Rosiglitazone can achieve the recuperation of the ability to concentrate radioiodine in 40% of patients when treatment is extended for 24 weeks.


REFERENCES

  1. Davies L, Welch GH. Increasing incidence of thyroid cancer in the United States 1973-2002. JAMA 2006; 265: 2164- 2167.

  2. Rizo-Ríos P, Sierra-Colindres MI, Vázquez-Piñón G, Cano- Guadiana M, Meneses-García A, Mohar A. Registro hospitalario de cáncer: Compendio de Cáncer 2000-2004. Cancerología 2007; 2: 203-287.

  3. Soh EY, Cark OH. Surgical considerations and approach to the thyroid cancer. Endocrinol Metab Clin N Am 1996; 25: 115-139.

  4. Mazzaferri EL. Long-term outcome of patients with differentiated thyroid carcinoma: Effect of Therapy. Endocr Pract 2000; 6: 469-476.

  5. Park JW, Clark OH. Redifferentiation therapy for thyroid cancer. Surg Clin N Am 2004; 84: 921-943.

  6. Matias-Guiu X, Cuatrecasas M, Musulen E, Prat J. p53 expression in anaplastic carcinomas arising from thyroid papillary carcinomas. J Clin Pathol 1994; 47: 337-339.

  7. Ito Y, Yoshida H, Nakano K, Takamura Y, Miya A, Kobayashi K, Yokozawa T, Matsuzuka F, Matsuura N, Kuma K, MiyauchiA. Syndecan-1 expression in thyroid carcinoma: stromal expression followed by epithelial expression is significantly correlated with dedifferentiation. Histopathology 2003; 43: 157-164.

  8. Ito Y, Yoshida H, Uruno T, Nakano K, Miya A, Kobayashi K, Yokozawa T, Matsuzuka F, Matsuura N, Kakudo K, Kuma K, Miyauchi A. Surviving expression is significantly linked to the dedifferentiation of thyroid carcinoma. Oncol Rep 2003; 10: 1337-1340.

  9. Coelho SM, Corbo R, Buescu A, Carvalho DP, Vaisman M. Retinoic Acid in patients with radioiodine non responsive thyroid carcinoma. J Endocrinol Invest 2004; 27: 334-339.

  10. Elisei R, Vivaldi A, Agate L, Ciampi R, Molinaro E. All-trans retinoic acid treatment inhibits the growth of RNA (beta) mRNA expressing thyroid cancer cell lines does not reinduce the expression of thyroid specific genes. J Clin Endocrinol 2005; 90: 2403-2411.

  11. Klopper JP, Hays WR, Sharma V, Baumbusch MA, HershmanJM, Haugen BR. Retinoid X receptor gamma and peroxisome proliferator-activated receptor-gamma expression predicts thyroid carcinoma cell response to retinoid and thiazolidinedione treatment. Mol Cancer Ther 2004; 3: 1011-1020.

  12. Auwerx J. PPAR, the ultimate thrifty gene. Diabetologia 1999; 42: 1033-1049.

  13. Bonofiglio D, Qi H, Gabriele S, Catalano S, Aquila S, Belmonte M. Peroxisome proliferator-activated receptor gamma inhibits follicular and anaplastic thyroid carcinoma cells growth by up regulating p21Cip1/WAF1 gene in a Sp1- dependent manner. Endocr Relat Cancer 2008; 15: 545-557.

  14. Ohta K, Endo T, Haraguchi K, Hershman JM, Onaya T. Ligands for peroxisome proliferated-activated receptor gamma inhibit growth and induce apoptosis of human papillary thyroid carcinoma cell. J Clin Endocrinol Metab 2001; 86: 2170-2177.

  15. Vidal-Puig A, Jiménez-Liñán M, Lowell BB, Hamann A, Hu E, Spiegelman B, Flier JS, Moller DE. Regulation of PPAR gene expression by nutrition and obesity in rodents. J Clin Invest 1998; 97: 2553-2561.

  16. Lefebvre AM, Laville M, Vega N, Riou JP, van Gaal L, Auwerx J, Vidal H. Depot-specific differences in adipose tissue gene expression in lean and obese subjects. Diabetes 1998; 47: 98-103.

  17. Rieusset J, Andreelli F, Auboeuf D, Roques M, Vallier P, Riou JP, Auwerx J, Laville M, Vidal H. Insulin acutely regulates the expression of peroxisome proliferator-activated receptor  in human adipocytes. Diabetes 1999; 48: 699-705.

  18. Kebebew E, Peng M, Reiff E, Treseler P, Woeber KA, Clark OH, Greenspan FS, Lindsay S, Duh QY, Morita E. A phase II trial of rosiglitazone in patients with thyroglobulin-positive and radioiodine-negative differentiated thyroid cancer. Surgery 2006; 140: 960-966.

  19. Tepmongkol S, Keelawath S, Honsawek S, Ruangvejvorachai P. Rosiglitazone effect on radioiodine uptake in thyroid carcinoma patients with high thyroglobulin but negative total body scan: A correlation with the expression of peroxisome proliferator-activated receptor-gamma. Thyroid 2008; 18: 697-704.

  20. Elias AN, Lizotte DO. Enhanced radioiodine uptake in a patient with poorly differentiated papillary thyroid cancer after treatment with rosiglitazone. Clin Nuc Med 2006; 31: 517-519.




2020     |     www.medigraphic.com